Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals

AUTHORS / AFFILIATIONS

Leire Egia-Mendikute[1,†], Alexandre Bosch[1,†], Endika Prieto-Fernández[1], So Young Lee[1], Borja Jimenez-Lasheras[1], Ana García del Río[1], Asier Antoñana-Vildosola[1], Chiara Bruzzone[2], Maider Bizkarguenaga[2], Nieves Embade[2], Nicola G A Abrescia[3,4,5], Jose M. Mato[2,5], Oscar Millet[2], Asis Palazon[1,4,*]

[1]Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Derio 48160, Bizkaia, Spain.

[2]Precision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Derio 48160, Bizkaia, Spain.

[3]Structure and Cell Biology of Viruses Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Derio 48160, Bizkaia, Spain.

[4]Ikerbasque, Basque Foundation for Science, Bilbao 48015, Bizkaia, Spain.

[5]Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid 28029, Spain.

*Correspondence: apalazon@cicbiogune.es | @asispalazon

[†]These authors contributed equally.

ABSTRACT

There is an ongoing need of developing sensitive and specific methods for the determination of SARS-CoV-2 seroconversion. For this purpose, we have developed a multiplexed flow cytometric bead array (C19BA) that allows the identification of IgG and IgM antibodies against three immunogenic proteins simultaneously: the spike receptor-binding domain (RBD), the spike protein subunit 1 (S1) and the nucleoprotein (N). Using different cohorts of samples collected before and after the pandemic, we show that this assay is more sensitive than ELISA. The combination of three viral antigens allows for the interrogation of full seroconversion. Importantly, we have detected N-reactive antibodies in COVID-19-negative individuals. Here we present a novel immunoassay that is easily implemented and has superior potential to detect low antibody titers compared to current gold standard serology methods.

INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) global spread has resulted in an ongoing pandemic (Zhou et al., 2020). To date, most immunoassays to determine seroconversion and measure antibody responses are based on enzyme-linked immunosorbent assay (ELISA). Serological assays are important to detect previously infected individuals and perform epidemiological seroconversion studies (GeurtsvanKessel et al., 2020; Lee et al., 2020; Theel et al., 2020). Moreover, they have important implications in the development of antibody-based therapeutics (i.e. convalescent serum or monoclonal antibodies) and vaccines (i.e. selection of non-immunised individuals and follow-up). For these reasons, there is a need of developing fast and sensitive serology assays that can be deployed at a large scale (Bryant et al., 2020).

SARS-CoV-2 contains several structural proteins, among them the Spike (S) and the Nucleoprotein (N) are the most immunogenic viral antigens and are used in serologic assays (Amanat and Krammer, 2020; Zhang et al., 2020). The S protein is comprised of two subunits: S1 and S2. S1 includes the receptor-binding domain (RBD) that binds to its cognate receptor angiotensin converting enzyme 2 (ACE2) expressed by host cells (Shang et al., 2020; Walls et al., 2020; Zost et al., 2020). Its sequence is specific for SARS-CoV-2, often generating neutralising antibodies in seropositive individuals (Chi et al., 2020). Given their specificity, both RBD and S are considered ideal for serology assays (Amanat et al., 2020; Premkumar et al., 2020; Stadlbauer et al., 2020), especially in the form of recombinant proteins produced in mammalian cell systems that reflect a physiological glycosylation pattern (Watanabe et al., 2020). Humoral immunity against SARS-CoV-2 has been reported (Ni et al., 2020), including the presence of neutralizing antibodies in seropositive individuals (Ju et al., 2020). Moreover, specific cellular responses have been described, including memory T cell formation against immunodominant peptides (Grifoni et al., 2020; Le Bert et al., 2020; Mateus et al., 2020).

In general, ELISAs have an acceptable specificity and sensitivity profile for performing large epidemiological studies, but lack the required accuracy for routine SARS-CoV-2 serology (Duong et al., 2020; Lisboa Bastos et al., 2020). Moreover, ELISAs have important limitations including cost, time and throughput. They require optimisation and the use of individual plates for each antigen or antibody class to be tested. Moreover, the antigen is immobilised to the plate, which can hide epitopes or increase the background noise. For these reasons, ELISAs are not well suited to detect low antibody titers and often give undetermined values that are close to the cut-off, leading to difficult interpretation of results.

Cytometric bead arrays offer an alternative to perform serology. This technology allows for the rapid identification of multiple analytes simultaneously on a multiplexed manner, requiring less amounts of sample than traditional immunoassays (Morgan et al., 2004). Its reproducibility and sensitivity are well characterised, especially for measuring cytokines (Leng et al., 2008). The readout is based on flow cytometry, open systems that are widely available in clinical and research settings.

In this study, we have developed a novel flow-cytometric bead array (C19BA) to assess seroconversion against SARS-CoV-2, leveraging the multiplex capability of this technology for the simultaneous interrogation of the presence of IgG and IgM antibodies against three viral antigens. The superior sensitivity of this approach unraveled the presence of N-reactive antibodies in a cohort of samples collected before the pandemic, indicating that cross-reactivity against this conserved viral protein exists.

METHODS

Serum samples

All serum samples were provided by the Basque Biobank (www.biobancovasco.org) after approval from the corresponding ethics committee (CEIC-E 20-26, 1-2016). All participants in the study provided informed consent and were anonymized. The COVID

cohort corresponds to 43 patients presenting COVID-19 symptomatology and diagnosed by PCR. The preCOVID cohort (50 serum samples) was obtained during the yearly medical check-up of the working population of the Basque Country in 2018-2019 in collaboration with Osarten Kooperatiba Elkartea from Mondragon Corporation.

Microbead coating

PMMA (polymethyl methacrylate) 8.2 µm microbeads coated with streptavidin were purchased from PolyAn (Cat#10652009). Each microbeads presented a different fluorescence intensity (Red4 dye, Excitation: 590-680 nm/Emission: 660-780 nm). First, microbeads were washed with cold PBS pH 7.2 (Gibco Cat#14190-094) by centrifugation at 2000 rpm for 5 min and resuspended in PBS. Then, biotinylated recombinant RBD, S1 and N (Acrobiosystems Cat#SPD-C82E9, Cat#S1N-C82E8 and Cat#NUN-C81Q6, respectively) were added to the tubes (RBD at 11 µg/mL, S1 at 30 µg/mL, N at 19,5 µg/mL) and kept at 4°C on rotating head over tail for an hour, protected from light. Positive control beads were coated with biotinylated human IgG (Novus Biologicals Cat#NBP1-96855) and IgM (Novus Biologicals Cat#NBP1-96989) on the same microbead at 15 µg/mL each. Negative control beads were not coated with protein. After the coupling reaction, microbeads were washed three times with PBS. Then, D-biotin (2 µM) (Sigma-Aldrich Cat#8512090001) was added and incubated for 15 min at room temperature (RT) to inactivate residual streptavidin. After three additional washes, equal amounts of each microbead were combined in the same vial.

C19BA assay

Antigen-coupled microbeads were added to protein LoBind 1.5 mL Eppendorf tubes (Eppendorf Cat#525-0133) in a volume of 50 µL of PBS containing a total of 5000-6000 beads. After centrifugation (2000 rpm, 5 min), microbeads were resuspended with 100 µL of pre-diluted (PBS) serum samples or serially diluted commercial antibodies against RBD (GenScript Cat#A02038) or N (Acrobiosystems Cat#NUN-S41) starting from a 1

mg/mL concentration. Negative control samples were prepared with PBS. After a 30 minute incubation (RT protected from light), samples were washed three times in PBS. Secondary antibodies were diluted in 100 µL of PBS containing 5% FBS: anti-human IgG-PE (1:50) (BD Biosciences Cat#555787) and anti-human IgM-BV421 antibodies (1:1000) (BD Biosciences Cat#555783). The mix was incubated with the samples for 15 min at RT protected from light. One final wash was performed, and microbeads were resuspended in 200 µL of PBS supplemented with 5% FBS for acquisition. At least 600 events for each type of microbead were acquired in a FACSymphony flow cytometer (BD Biosciences) and geometric mean fluorescence intensities (gMFI) were obtained. Results were analyzed using FlowJo version 10 (BD Biosciences).

ELISA

The protocol was adapted from a previously established immunoassay (Stadlbauer et al., 2020). Briefly, 96-well ELISA plates (Nunc Maxisorp Cat#44-2404-21) were coated overnight at 4°C with 50 µL of biotinylated RBD, S1 or N protein (Acrobiosystems), at 2 µg/mL (for RBD and S1) or 1.4 µg/mL (N) in PBS (Gibco). Then, the coating solution was removed and plates were blocked with 3% non-fat milk in PBST (PBS plus 0.1% Tween-20) for 1 hour at RT. Serum samples were pre-diluted in 1% non-fat milk in PBST, and incubated for 2 hours at RT. After three washes with 250 µL of PBST in a plate washer (Biotek), each well was incubated with an anti-human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (1:5000) (GenScript Cat#A01854) or anti-human IgM-HRP (Novus Biologicals Cat#NBP1-75014) for 1 hour at RT. Plates were washed three times with PBST, and 100 µL of TMB substrate (Thermo Scientific Cat#34021) were added to each well, incubated for 2 min and the reaction was stopped with 50 µL of stop solution (Thermo Scientific Cat# N600). The optical density (OD) was measured at 450 nm in a VictorNivo multimode plate reader (PerkinElmer).

Statistical Analysis

To calculate the sample ODs and gMFIs, the values corresponding to the negative controls were substracted from all samples. For values below 0.11, the OD or gMFI values were set at 0.11 in order to calculate the AUC and generate the graphs. Statistical analyses comparing the preCOVID and COVID cohorts were performed with an unpaired two-tailed Student's t-test. Data were analyzed using Prism 8 (GraphPad). Phylogram generated from the FASTA alignment file was performed using FastTree (https://www.genome.jp/).

RESULTS

Development of a flow cytometric bead array (C19BA) for the detection of SARS-CoV-2 seroconversion

The presented flow cytometry assay consists in a multiplexed array containing microbeads with different intrinsic fluorescence intensities coated with viral antigens. The coupling was performed with microbeads functionalized with streptavidin and proteins tagged with a unique terminal biotin, which allows for the orientation of the antigen on the surface of the bead. The bead array (C19BA) is incubated with serum samples to allow the binding of anti-SARS-CoV-2 antibodies and then stained with anti-IgG and anti-IgM secondary antibodies labelled with different fluorochromes (Figure 1A). In order to fully assess the specific seroconversion against SARS-CoV-2, we have chosen RBD, S1 and N as target antigens. The redundancy of RBD as a sequence included in S1 allows for the confirmation of intra-assay specificity on different microbeads simultaneously. The N protein was also included in the assay because of its immunogenicity. N is predicted to be less specific for SARS-CoV-2 based on the analysis of the sequence alignment with other coronavirus family members (Supplemental Information Figure 1). We reasoned that fully seroconverted individuals would present antibodies against the three chosen antigens. C19BA includes uncoated negative control beads and positive control beads that are coated with human IgG and IgM (Figure 1B). This setup differentiates each type of microbead as shown in the non-overlapping histograms in

Figure 1C. We first tested the ability of this assay to identify recombinant IgG antibodies against RBD and N. As can be seen on Figure 1D, the microbead array clearly identified the binding of these antibodies. Importantly, the sensitivity of C19BA was superior to ELISA (Figure 2) when their performance was compared in serial dilutions of recombinant anti-RBD and anti-N IgG antibodies. C19BA presented a better broader dynamic range and identified low antibody concentrations that were not detected by ELISA.

Determination of SARS-CoV-2 seroconversion on preCOVID-19 and COVID-19 cohorts by C19BA

We then applied C19BA to interrogate serum samples from a cohort of 43 individuals who tested positive by PCR for SARS-CoV-2 infection that were obtained at the time of hospital admission (COVID cohort). As a control, sera from 50 individuals collected before the pandemic (2018-2019) were analysed (preCOVID cohort). Both ELISA and C19BA were able to discriminate both cohorts based on the presence of IgG and IgM antibodies against RBD, S1 and N. At this early stage of infection, not all samples from the COVID cohort presented reactivity against viral antigens (Supplemental Information Figure 2). Serial dilutions of 10 seropositive COVID and 10 preCOVID samples were performed to further compare the sensitivity of C19BA versus ELISA. Figure 3A shows the dilution curves corresponding to the presence of IgG antibodies by these two methods. C19BA was superior to ELISA separating both cohorts and identifying the presence of antibodies at lower concentrations. This was confirmed by plotting the area under the curve (AUC) and determining its statistical significance (Figure 3B). The titers of IgM antibodies were lower than IgG as measured by both methods (Figure 3C-D), in line with previous studies (Ni et al., 2020). Importantly, our assay identified the presence of N-reactive IgG antibodies in preCOVID samples, although in general at lower titers than in the COVID cohort (Figure 3A-B). Figure 4 shows representative dot plot profiles corresponding to preCOVID and COVID samples. While the reactivity against RBD and

S1 was specific for COVID samples, cross-reactivity against N was observed in some preCOVID individuals that contained IgG, but not IgM antibodies. In the COVID cohort, several samples that presented full seroconversion against RBD, S1 and N for both IgG and IgM were identified. A minority of COVID samples presented only N-reactive IgG and IgM antibodies, testing negative for RBD and S1 (Figure 4).

DISCUSSION

Sensitive characterization of humoral responses is critical to control the current pandemic (Theel et al., 2020), because it allows to perform accurate longitudinal serosurveys and epidemiological studies. Moreover, antibodies act as biomarkers for previous exposure and thus can guide vaccination strategies, including booster dosing. Serology assays need to be cost-effective, high-throughput, scalable and easy to implement. In order to fullfill all these requirements, we have developed an assay that combines three viral antigens with superior sensitivity than ELISA. The combination of antigens allows for the interrogation of full seroconversion, including the presence of antibodies against the partially redundant and specific RBD and S1 antigens, and the more conserved but strongly immunogenic N protein (Timani et al., 2004).Together, these antigens offer a more specific and rapid platform than conventional assays that use only one viral antigen or require two-step sequential confirmation. Spike-reactive antibodies have neutralization capacity, even when binding non-RBD Spike epitopes (Liu et al., 2020). On the other hand, N-reactive antibodies are not considered to confer protection and might even be predictive of poor patient outcome in some cases (Atyeo et al., 2020; Yasui et al., 2008).

Another key feature of robust serology assays is sensitivity, which is important to detect low antibody titers. ELISA assays often identify samples with low OD values that are close to the established cut-off, resulting in inconclusive or false positive results. These require repetition of the assay and titration of samples. A previously developed ELISA includes a sequential confirmatory assay with the Spike after positivity against RBD

(Amanat et al., 2020). We demonstrate that C19BA presents a superior dynamic range than ELISA, with better sensitivity at lower antibody titers. Indeed, the method presented here is able to detect the presence of antibodies against three different viral antigens at dilutions that were beyond the limit of detection of ELISA.

This superior sensitivity allowed for the identification of low titers of N-reactive antibodies in Covid-19 naïve individuals, which were likely generated as a result of a common cold coronavirus infection. This fact raises important concerns about the specificity of the use of N protein for serological assays, given its high homology with N proteins of other coronaviruses. Indeed, several studies reported similar cross-reactivity on serological testing based on N protein during the previous SARS-CoV outbreak in 2004, resulting in false positives (Patrick et al., 2006; Woo et al., 2004).

Although the majority of seropositive individuals in the COVID cohort presented antibodies reactive against RBD, S1 and N; a minority of samples only presented N-reactive antibodies. This suggests that these individuals either had remanent antibodies from previous primary infections, or mounted fast secondary antibody responses against N after mobilization of memory B cells generated as a result of a previous coronavirus infection. Recently, in a similar fashion, N-specific memory T cells have been also identified in COVID-19 unexposed individuals (Le Bert et al., 2020). Together, these data provide evidence that cellular and humoral immune responses against SARS-CoV-2 exist as a result of crossreactivity against the N protein originated by previous coronavirus infections. The impact of these pre-existing T cell and antibody responses in the control and pathogenesis of COVID-19 requires further investigation.

In summary, we have developed a novel multiplexed method with higher sensitivity than traditional serology assays, using a triple combination of antigens that exploits the specificity of the Spike and RBD together with the less-specific N protein for the detection of antibodies against SARS-CoV-2.

ACKNOWLEDGEMENTS

We thank Petros Tyrakis and Iván Martínez-Forero for critical reading and editing of the manuscript. Grant support: Support was provided by the Severo Ochoa Excellence Accreditation from MCIU (SEV-2016-0644) and the SPRI I+D COVID-19 fund (Gobierno Vasco). OM-JMM and NGAA acknowledge the Agencia Estatal de Investigación (Spain) for grants CTQ2015-68756-R, RTI2018-101269-B-I00 and RTI2018-095700-B-I00, respectively. AP has received funding from the European Research Council (ERC) grant agreement number 804236 (Horizon 2020), and the FERO Foundation.

AUTHOR CONTRIBUTIONS

A.P. conceived and administered the project. L.E.M. and A.B. performed all experiments and analysed data. A.B., L.E.M., N.G.A.A. and E.P. performed computational and statistical analyses. A.G.D.R., S.Y.L., B.J.L. and A.A.V. contributed ideas. O.M., J.M.M., C.B., M.B. and N.E. provided patient samples. A.P. and E.P. wrote the manuscript with help from all co-authors.

DECLARATION OF INTEREST

The authors declare no competing interests.

REFERENCES

1. Amanat, F., and Krammer, F. (2020). SARS-CoV-2 Vaccines: Status Report. Immunity *52*, 583-589.
2. Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T.H.O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G.A., Jurczyszak, D., Polanco, J.*, et al.* (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med.

3. Atyeo, C., Fischinger, S., Zohar, T., Slein, M.D., Burke, J., Loos, C., McCulloch, D.J., Newman, K.L., Wolf, C., Yu, J.*, et al.* (2020). Distinct early serological signatures track with SARS-CoV-2 survival. Immunity.
4. Bryant, J.E., Azman, A.S., Ferrari, M.J., Arnold, B.F., Boni, M.F., Boum, Y., Hayford, K., Luquero, F.J., Mina, M.J., Rodriguez-Barraquer, I.*, et al.* (2020). Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci Immunol *5*.
5. Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y.*, et al.* (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science.
6. Duong, Y.T., Wright, C.G., and Justman, J. (2020). Antibody testing for coronavirus disease 2019: not ready for prime time. BMJ *370*, m2655.
7. GeurtsvanKessel, C.H., Okba, N.M.A., Igloi, Z., Bogers, S., Embregts, C.W.E., Laksono, B.M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J.*, et al.* (2020). An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun *11*, 3436.
8. Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S.*, et al.* (2020). Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell *181*, 1489-1501 e1415.
9. Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S.*, et al.* (2020). Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature.
10. Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin, M., Tan, N., Linster, M.*, et al.* (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature.

11. Lee, C.Y., Lin, R.T.P., Renia, L., and Ng, L.F.P. (2020). Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. Front Immunol *11*, 879.
12. Leng, S.X., McElhaney, J.E., Walston, J.D., Xie, D., Fedarko, N.S., and Kuchel, G.A. (2008). ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci *63*, 879-884.
13. Lisboa Bastos, M., Tavaziva, G., Abidi, S.K., Campbell, J.R., Haraoui, L.P., Johnston, J.C., Lan, Z., Law, S., MacLean, E., Trajman, A.*, et al.* (2020). Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ *370*, m2516.
14. Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J.F., Sahi, V., Figueroa, A.*, et al.* (2020). Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature.
15. Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S.I., Dan, J.M., Burger, Z.C., Rawlings, S.A., Smith, D.M., Phillips, E.*, et al.* (2020). Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science.
16. Morgan, E., Varro, R., Sepulveda, H., Ember, J.A., Apgar, J., Wilson, J., Lowe, L., Chen, R., Shivraj, L., Agadir, A.*, et al.* (2004). Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol *110*, 252-266.
17. Ni, L., Ye, F., Cheng, M.L., Feng, Y., Deng, Y.Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X.*, et al.* (2020). Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity *52*, 971-977 e973.
18. Patrick, D.M., Petric, M., Skowronski, D.M., Guasparini, R., Booth, T.F., Krajden, M., McGeer, P., Bastien, N., Gustafson, L., Dubord, J.*, et al.* (2006). An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus. Can J Infect Dis Med Microbiol *17*, 330-336.

19. Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D.R., Raut, R., Markmann, A., Cornaby, C., Bartelt, L., Weiss, S., Park, Y.*, et al.* (2020). The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol *5*.
20. Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., and Li, F. (2020). Structural basis of receptor recognition by SARS-CoV-2. Nature *581*, 221-224.
21. Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G.A., Tan, J., Bhavsar, D., Capuano, C., Kirkpatrick, E.*, et al.* (2020). SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol *57*, e100.
22. Theel, E.S., Slev, P., Wheeler, S., Couturier, M.R., Wong, S.J., and Kadkhoda, K. (2020). The Role of Antibody Testing for SARS-CoV-2: Is There One? J Clin Microbiol *58*.
23. Timani, K.A., Ye, L., Ye, L., Zhu, Y., Wu, Z., and Gong, Z. (2004). Cloning, sequencing, expression, and purification of SARS-associated coronavirus nucleocapsid protein for serodiagnosis of SARS. J Clin Virol *30*, 309-312.
24. Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell *181*, 281-292 e286.
25. Watanabe, Y., Allen, J.D., Wrapp, D., McLellan, J.S., and Crispin, M. (2020). Site-specific glycan analysis of the SARS-CoV-2 spike. Science *369*, 330-333.
26. Woo, P.C., Lau, S.K., Wong, B.H., Chan, K.H., Hui, W.T., Kwan, G.S., Peiris, J.S., Couch, R.B., and Yuen, K.Y. (2004). False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide. J Clin Microbiol *42*, 5885-5888.

27. Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T.*, et al.* (2008). Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol *181*, 6337-6348.
28. Zhang, W., Du, R.H., Li, B., Zheng, X.S., Yang, X.L., Hu, B., Wang, Y.Y., Xiao, G.F., Yan, B., Shi, Z.L., and Zhou, P. (2020). Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect *9*, 386-389.
29. Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L.*, et al.* (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature *579*, 270-273.
30. Zost, S.J., Gilchuk, P., Chen, R.E., Case, J.B., Reidy, J.X., Trivette, A., Nargi, R.S., Sutton, R.E., Suryadevara, N., Chen, E.C.*, et al.* (2020). Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med.

FIGURES



Figure 1. Workflow and performance of C19BA. **(A)** Overview of the detection of SARS-CoV-2 seroconversion by flow cytometric bead array. Streptavidin-coated microbeads with different fluorescence intensities are conjugated with recombinant biotinylated viral antigens (RBD, S1 and N) and mixed and incubated with prediluted serum samples together with control beads. After incubation, microbeads are washed and stained with

anti-human IgG and IgM secondary antibodies, washed and acquired on a flow cytometer for downstream analysis. **(B)** Dot plots showing the staining patterns of positive (red) and negative (black) control beads with secondary anti-IgG-PE, anti-IgM-BV421 or both. The signal corresponding to IgG-PE (top) and IgM-BV421 (bottom) is shown for each column. **(C)** Histogram showing the distribution of the microbeads based on their intrinsic fluorescence on the APC channel. Each colour represents the coating for each microbead. **(D)** Representative dot plots showing the specificity of the staining pattern of recombinant anti-RBD IgG (left) or anti-N IgG (right) antibodies.



Figure 2. C19BA has superior sensitivity and greater dynamic range than ELISA. Comparison of the titration of anti-RBD (blue and green) and anti-N (orange) IgG antibodies against recombinant RBD, S1 and N proteins by C19BA (top) and ELISA (bottom). The mean value of two replicates is shown, error bars represent SD.



Figure 3. Identification of SARS-CoV-2 IgG and IgM seroconversion by C19BA. **(A)** Titration curves of the reactivity of individual serum samples against RBD, S1 and N proteins measured by flow cytometry against IgG by C19BA (top) and ELISA (bottom) for each cohort: preCOVID (red, n=10) and COVID (black, n=10). **(B)** AUC values for the experiment shown in (A). **(C)** Titration curves of the reactivity of individual serum samples against RBD, S1 and N proteins against IgM by C19BA (top) and ELISA (bottom). **(D)** AUC values for the experiment shown in (C). Statistical analyses were performed using an unpaired two-tailed Student's t-test. Asterisks represent p values (*** p<0.001, * p<0.05, ns: not significant). Horizontal lines represent median values.



Figure 4. C19BA reveals different serology patterns in preCOVID and COVID samples. Dot plots showing IgG (top) and IgM (bottom) reactivity against RBD, S1 and N for representative preCOVID and COVID samples.

SUPPLEMENTAL INFORMATION



Figure S1. Conservation of the N protein sequence across different members of the Coronaviridae family. **(A)** Alignment of the sequences (Uniprot codes: SARS-CoV-2, P0DTC9; SARS-CoV-1, P59595; MERS-CoV-1, R9UM87; OC43, P33469; 229E, P15130; NL63, Q6Q1R8; and UKU1, Q5MQC6) using Clustal Omega and represented

using ESPRIPT 3.0 software using the 70% of equivalent residues calculated per columns, considering physico-chemical properties; on top of the sequences the secondary structural elements derived from the 3D structures determined for the RNA-binding domain (PDB ID: VYO) and the C-terminal dimerization domain (PDB ID: 6WJI) and corresponding to the most conserved regions. **(B)** Phylogram generated from the FASTA alignment file using FastTree (https://www.genome.jp/). The two columns on the right represent the sequence identity and similarity in a pairwise alignment with the SARS-CoV-2.



Figure S2. Serological responses against RBD, S1 and N measured by C19BA and ELISA. **(A, B)** gMFI values obtained by C19BA (top) and OD values obtained by ELISA (bottom) for the same samples for IgG (A) and IgM (B). Statistical analyses were performed using an unpaired two-tailed Student's t-test to compare the preCOVID (red, n=50) and COVID (black, n=43). Asterisks represent p values (*** $p<0.001$, * $p<0.05$, ns: not significant). Horizontal lines represent median values.